Study of BHV-1400 in IgA Nephropathy

Part of paid clinical trials in Farmington, Connecticut.

Sponsor
Biohaven Therapeutics Ltd.
Study ID
NCT07054684
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • BHV-1400 — DRUG
    BHV-1400 is delivered subcutaneously (SC)

Study Details

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

Key Dates

Start date
Jul 30, 2025
Status verified
May 2026
Primary completion
Jul 31, 2027
Completion
Jul 31, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: BHV-1400

Primary Outcome Measure

Number of participants with Serious AEs (SAEs), AEs leading to discontinuation, deaths [ Time Frame: Up to 1 year ]

Central Contacts

Locations (14)

FacilityCityStateZIPSite coordinators
Site-001FarmingtonConnecticut06030-
Site-003Miami LakesFlorida33016-
Site-011Miami LakesFlorida33172-
Site-013OrlandoFlorida32806-
Site-005Pembroke PinesFlorida33029-
Site-008LawrencevilleGeorgia30046-
Site-009HinsdaleIllinois60521-
Site-012IndianapolisIndiana46268-
Site-015ShelbyMichigan48316-
Site-006ChesterfieldMissouri63017-
Site-002Dakota DunesSouth Dakota57049-
Site-004HoustonTexas77099-
Site-014HoustonTexas77027-
Site-016Salt Lake CityUtah84115-

Find similar trials in Farmington, CT

By research site
Site-001· Farmington, CTSite-003· Miami Lakes, FLSite-011· Miami Lakes, FLSite-013· Orlando, FLSite-005· Pembroke Pines, FLSite-008· Lawrenceville, GA

Related Studies